Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
Demo Company

Wide Variety of Gels Can Now Be Analyzed With One Imaging System

By BiotechDaily International staff writers
Posted on 27 Mar 2013
Image: GelDoc-Ite, the new imaging system for gel documentation from UVP (Photo courtesy of UVP, LLC).
Image: GelDoc-Ite, the new imaging system for gel documentation from UVP (Photo courtesy of UVP, LLC).
A new high-quality gel imager provides flexible, simple, efficient, and economical imaging, analysis, and documentation within a single system.

UVP, LLC (UVP; Upland, CA, USA) introduces its new “GelDoc-Ite Imager” designed for fast, simple imaging of various gel types. This imager "provides researchers with a resourceful and economical system [while] hardware features facilitate ease of use [...]. Side access doors are conveniently located for cutting or moving gels, a UV-safe gel viewer window enables viewing of illuminated gels, and a camera and zoom lens configuration captures large gels or zooms in on details," said UVP management team member Mike Capps.

The integrated UV transilluminator accommodates a wide range of gel sizes and samples are illuminated with a choice of transilluminator for maximizing fluorophore stain excitation. A unit with midrange 302 nm UV is for viewing ethidium bromide (EtBr) and other stains, while the 3UV model provides user-selectable 302, 365, and 254 nm excitation. An EtBr emission filter is included as standard with the GelDoc-Ite, while a variety of optional emission filters are available to suit various applications. The modular design enables placement of converter plates onto the UV transillumination surface, converting midrange UV to specific wavelengths for illumination of a variety of stains. The “Visi-Blue” Converter Plate converts the UV to 460–470 nm blue light for viewing stains such as SYBR Green, SYBR Safe, and GelGreen. When white light transillumination is required, the White Light Converter Plate can be used for viewing gels such as Coomassie Blue and Silver stain.

GelDoc-Ite simplifies imaging with the intuitive, workflow-based “VisionWorks LS” software. Easy-to-use one-touch buttons enable fast image acquisition, while the software controls the scientific grade CCD camera, which captures high quality, publication-ready images. Researchers can conduct 1D analysis and generate extensive quantitative data using molecular weight, histograms, lane profile graphs and other tools. Once analysis is complete, exporting result data to Excel and other programs for documentation and publication is accomplished with the software's integrated export tools.

With its compact size, the GelDoc-Ite Imager greatly reduces lab bench-space requirements and, with its user-friendly system, minimal operator training is required. Its design enables researchers to easily view gels using multiple light sources, to quickly capture and save publication-quality images, and to analyze lanes and bands. Fluorescent, colorimetric, or blue light imaging of a wide variety of gels can now be satisfied within this single system.

Related Links:

UVP, LLC
GelDoc-Ite



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.